Myotonic dystrophy
RecruitingStudy of intravenous AOC 1001 to evaluate long-term safety and effectiveness in patients with myotonic dystrophy type 1
Study of intravenous AOC 1001 to evaluate long-term safety and effectiveness in patients with myotonic dystrophy type 1
- Disease:Myotonic dystrophy
- Substances:Humanised Igg1 Monoclonal Antibody Against Tfr1 Conjugated To Double Stranded Sirna Oligonucleotide Against Dmpk Via A Non-Cleavable Linker
The Netherlands- Participants:0–17 years · 18–64 years
- Substances:Humanised Igg1 Monoclonal Antibody Against Tfr1 Conjugated To Double Stranded Sirna Oligonucleotide Against Dmpk Via A Non-Cleavable Linker
- Sponsor:Avidity Biosciences Inc.










